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Abstract 
 
Autoimmune diseases are characterized by the development of autoreactive T- and B-cells 
targeting self-antigens, which eventually can result in chronic and persistent organ damage. 
The autologous hematopoietic stem cell transplantation (AHSCT) opened new avenues in the 
treatment of patients with severe, treatment-resistant autoimmune diseases. This paper 
reviews the immune-regulatory mechanisms behind AHSCT, and also summarizes the 
experiences of clinical practice related to the therapy in organ-specific and systemic 
autoimmune diseases. 
It seems that the intricate interplay of various immune competent cells with regulatory 
capacity control in a synergistic manner the repopulated immune system after AHSCT, which 
potentially leads to a significant clinical improvement in certain autoimmune diseases. 
However, the widespread use of AHSCT was intrinsically limited, due to the serious side-
effects of conditioning treatment and relatively high treatment-related mortality; moreover, 
the development of new effective and safe therapeutic approaches and the dawn of biological 
agents further limited its indications in the last decade. Nevertheless, with an appropriate 
patient selection and increased experience of transplant centres, the risks can be minimized, 
and AHSCT remained still a reasonable choice in multiple sclerosis and systemic sclerosis 
when the conventional therapy failed and further progression of disease is inevitable. 
 
Keywords: autoimmune diseases; autologous hematopoietic stem cell transplantation; clinical 
response; immunological background 
 
 3 
1. Introduction 
 
Autoimmune diseases are common clinical conditions arising from an abnormal immune 
response against self-structures of the body. The breakdown of peripheral and central immune 
tolerance results in the generation and activation of autoreactive T- and B-cells, which leads 
to tissue damage and functional loss under appropriate conditions [1]. In order to normalize 
the derailed immune responses, a wide set of immune-modulating agents, anti-inflammatory 
and immunosuppressive drugs including biological therapies were developed in the last 
decades. Although disease progression can be decelerated, even temporarily stopped with the 
aforementioned treatments, the autoimmune diseases cannot be cured. Expectation for a 
complete healing have turned the attention to novel therapeutic approaches, such as 
autologous hematopoietic stem cell transplantation (AHSCT), which opened new avenues for 
the treatment of autoimmune diseases [2].  
The rationale involves non-specific abrogation of autoreactive T- and B-cell responses by the 
use of high dose immunosuppression during conditioning and the successful reconstitution of 
a new and tolerant immune system by the re-infusion of hematopoietic stem cells [3]. 
However, the application of non-myeloablative AHSCT, with a more tolerable conditioning 
regimen, carries less risk in autoimmune diseases and associates with lower treatment-related 
mortality (TRM) compared to myeloablative procedure. Generally, AHSCT is beneficial in 
those conditions, where the loss of immune tolerance is pivotal in the pathogenesis, and 
tolerance induction is important in the deceleration of ongoing immune-processes.  
 
 
 
 
 4 
2. AHSCT in autoimmune diseases: the underlying immunological mechanisms 
 
Autoimmune diseases are characterized by faulty immune tolerance mechanisms, leading to 
the escape of autoreactive T- and B-cell clones, self-perpetuating proinflammatory cascades 
and eventually tissue damage. A crucial aspect of hematopoietic stem cell transplantation 
therefore is to achieve tolerance induction in autoimmune diseases, opposed to hematological 
malignancies where the major goal is to repopulate the myeloid and lymphoid lineages post 
conditioning regimens. Interestingly stem cells have been shown to mediate cell death of host-
derived T-cells, which presumably can be executed by antigen-presenting cells. This T-cell 
deletion takes place both in the peripheral, as well as in the central T-cell pool in thymus [4]. 
Animal models aid in understanding the molecular mechanisms behind transplantation. A 
special sort of animal models of autoimmunity, denoted as antigen-induced disease models 
are characterized by autoreactive T- and B-cell clones, where stable remission could be 
achieved. Other models of autoimmunity, the spontaneously developing animal models where 
defective immune tolerance plays a minor role, stem cell transplantation seemed ineffective. 
These animal models are characterized by stem cell disorders. During AHSCT the previously 
existing lymphocyte subsets are eliminated and the adaptive immune system is rebuilt from 
the T- and B-cell repertoires by newly formed cells. It has been shown previously that 
following stem cell transplantation cells of the immune system are repopulated in a particular 
order. Cyctotoxic T-cells, B-cells and natural killer(NK) cells reconstitute rapidly and 
completely, however CD4+ T-cells appear later in time, and this repopulation can also be 
incomplete. Following conditioning and AHSCT, T-cell receptor (TCR) rearrangement 
analyses indicate that the previous autoreactive T-cell repertoire is deleted giving raise of 
novel, non-autoreactive T-cells to repopulate. TCR rearrangement analyses, as well as the 
assessment of the cellular repopulation clearly shows a robust post-transplant modifications of 
 5 
the adaptive immune system. Naturally, these AHSCT-related molecular transformations also 
lead to the elimination of autoreactive B-cells besides T-lymphocytes, in addition to that 
transplantation promotes the development of novel lymphocyte subset distribution. In other 
words, these processes altogether can re-establish self-tolerance and quench previously 
existing autoimmune processes. Presumably following AHSCT regulatory T-cells also 
contribute to the development of immune tolerance in these patients [5,6]. On the other hand, 
the complete elimination of these autoreactive T-cells is impossible, and autoreactive clones 
still persist in the host after even myeloablative conditioning therefore autoreactive T-cell 
clones can be repopulated in some extent. An important physiological mechanism of the 
immune system, denoted as homeostatic proliferation also contribute to the repopulation of 
non-autoreactive T- and B-cell clones post transplantation. Graft T- and B-cells therefore can 
expand rapidly after being transferred into immunodeficient hosts by homeostatic 
proliferation. Severe lymphopenia following conditioning regimens leads to homeostatic 
proliferation. T-helper (Th)17 cells have been described to be associated with autoimmune 
processes. Following transplantation, CD4+ T-cells can be activated and subsequently 
progress to become Th17 cells [7]. However, only few percent of patients with autoimmune 
diseases relapse following transplantation. Based on reports from animal models, as well as 
humans the most plausible explanation could be that in parallel regulatory T-cells (Tregs) 
arise and silence pro-inflammatory/autoimmune processes driven by Th17 cells, and 
decelerate the development of autoreactive T-cell clones [8-11]. A selective and preferential 
Treg expansion controls autoreactive T- and B-cell clones in the repopulated lymphocyte 
repertoire [11]. On the other hand, although after conditioning treatment and subsequent 
AHSCT various regulatory cell-based controlling/protection mechanisms are activated, it 
cannot completely prevent disease recurrence because these autoimmune diseases have a 
specific genetic makeup still driving autoreactive processes, giving raise of autoreactive 
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lymphocyte clones. A certain hierarchy in cell repopulation has been described following 
transplantation. The first line of repopulated cells are members of the innate immune system, 
giving a quick, however less sophisticated immunological protection to the patients. 
Monocytes are the first cells to engraft, with a subsequent repopulation by granulocytes, and 
NK cells. The repopulation process shows very special dynamics. Cells of the innate immune 
system, such as myeloid cells or NK cells have been described to appear just within weeks 
after AHSCT, while the recovery of the sophisticated adaptive immune system needs more 
time [12,13]. Approximately a month after transplantation, lymphocyte counts normalize. 
However, it has been shown that, the functional readiness and efficacy of lymphocytes can be 
impaired for years following AHSCT [12,13]. Interestingly the number of Tregs of SLE 
patients who achieved complete remission after AHSCT seems to be steadily increasing. 
Regarding T-cells with regulatory capacity, in patients following AHSCT, both the 
conventional Tregs (CD4+CD25+ Foxp3+), as well as an unusual phenotype, CD8+ Foxp3+ 
Treg cell subsets have been shown to normalize, accompanied by the functional silencing of 
pathogenic T-cell responses to anti-nuclear antigens [14]. We have previously described that 
the frequency of Tregs did not change significantly after AHSCT, which raises the possibility 
that qualitative, rather than quantitative changes in the Treg repertoire are responsible for 
autoreactivity-control in patients with autoimmune diseases [15]. Besides the aforementioned 
immune cell subsets with regulatory capacity, the role of other cell types (e.g. tolerogenic 
dendritic cells, suppressor macrophages, or other myeloid-derived suppressor cells) cannot be 
excluded to play a beneficial role following stem cell transplantation in patients with 
autoimmune diseases [16-18]. 
Altogether it seems that the intricate interplay of various immune competent cells with 
regulatory capacity control in a synergistic manner the repopulated immune system, giving 
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hope that this therapeutic possibility will be a beneficial alternative in patients with 
autoimmune diseases.    
 
 
3. Clinical efficacy of AHSCT in autoimmune diseases 
 
In a number of onco-hematological diseases, such as Hodgkin’s, non-Hodgkin’s lymphoma 
and multiple myeloma, AHSCT may lead to remission or complete cure. In the last two 
decades, AHSCT appeared in the therapeutic repertoire of therapy-resistant autoimmune 
diseases. Numerous phase I and II trials were launched in certain autoimmune conditions and 
several thousand patients have been registered in various databases. In Europe, based on the 
database of the European Society for Blood and Marrow Transplantation (EBMT), more than 
2000 patients with autoimmune disease received AHSCT so far (Table 1) [19]. Based on the 
promising outcomes of studies, AHSCT can be a reasonable choice when the conventional 
therapy failed in certain autoimmune diseases, such as systemic sclerosis and multiple 
sclerosis. 
 
3.1 Systemic sclerosis 
Systemic sclerosis (SSc) is a progressive systemic autoimmune disease. The characteristics of 
SSc include autoreactive immune activation, vascular abnormalities and increased fibroblast 
activity leading to excessive extracellular matrix deposition. The fibrotic and inflammatory 
processes are prominent in the skin and certain internal organs, such as heart, lungs or kidneys 
[20,21]. SSc can be classified into two clinical subsets: the diffuse cutaneous form is 
characterized by rapidly progressive fibrosis of skin and visceral organs, while in limited 
cutaneous form, the extension of fibrosis is limited and the disease progression is slow [22]. 
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Since the therapeutic options are limited to the treatment of the complications, thus 
decelerating disease progression by stopping fibrosis is still an unsolved issue primarily in the 
diffuse cutaneous form. 
The majority of patients treated with AHSCT had diffuse cutaneous form with a rapid disease 
progression and early kidney and/or lung involvement. In recent years, the treatment-related 
mortality has been improved to 5-6% due to the careful patient selection [23]. The relatively 
good general health status is fundamental in reducing transplant-related mortality; moreover, 
in order to achieve the best clinical results, AHSCT should be applied before the development 
of any irreversible organ damage. As the consequence of improving safety and efficacy of 
treatment, the number of SSc patients received AHSCT procedures increased rapidly in the 
past few years, and present days, there are more than 430 registered SSc patients, who 
undergone AHSCT in Europe. In the past 15 years, numerous phase I/II trials were reported. 
One of the earliest multicenter open phase I/II study on AHSCT evaluated the results of 41 
SSc patients [24]. The results were promising, 69% of patients showed an improvement in 
skin score of >25% after transplantation; however, 17% of patients died related to the 
procedure. A few years later, the EBMT/EULAR report analysed the durability of the 
responses after AHSCT for severe SSc [25]. Fifty-seven patients with SSc, treated by HSCT 
in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow-up 
were included. After 22.9 months, partial or complete response was seen in 92%; however, 
35% of them relapsed within 10 months after AHSCT. Of note, TRM was only 8.7%; 
furthermore, and at 5 years, the probability of progression was 48% and the estimated survival 
was 72%. Based on smaller trials, the clinical amelioration induced by AHSCT includes 
improvement in the extent of skin fibrosis, as well as in capillary microcirculation, besides the 
expected anti-inflammatory effects. In the majority of the treated SSc patients, the modified 
Rodnan skin score (mRSS) was decreased by more than 20% after the treatment; however, the 
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effect of AHSCT on the status of affected visceral organs is limited to stabilization or 
moderate improvement only [26-28]. Until now, three randomized control trials assessed the 
safety and long-term clinical effects of AHSCT in SSc. The American Scleroderma Stem cell 
versus Immune Suppression Trial (ASSIST) compared the results of autologous non-
myeloablative HSCT with the effects of monthly administered pulse intravenous 
cyclophosphamide therapy [29]. After randomization, 10 patients underwent AHSCT, while 9 
control patients received 6 monthly pulses of cyclophosphamide. All patients received 
AHSCT showed significant improvements, while 8 control individuals had disease 
progression. The results of two-year follow-up after AHSCT suggested that improvements in 
skin score and forced vital capacity were persistent. The Autologous Stem cell 
Transplantation International Scleroderma Trial (ASTIS) was the first phase III trial in SSc 
[30]. A total of 156 patients were randomly assigned to receive AHSCT (n=79) or 12-monthly 
pulses of intravenous cyclophosphamide (n=77). The ASTIS trial demonstrated an 
improvement in both event-free and overall survival rates in AHSCT group. During a median 
follow-up of 5.8 years, 19 deaths and 3 irreversible organ failures occurred in AHSCT group, 
while in the control group 23 deaths and 8 irreversible organ failures were recorded. Among 
patients with early diffuse cutaneous form, AHSCT was associated with increased treatment-
related mortality in the first year after treatment. Overall, there were 8 AHSCT-related deaths 
(10%) in the study, but on the other hand, AHCST had a significant long-term event-free 
survival benefit. The Scleroderma: Cyclophosphamide Or Transplantation (SCOT) trial is the 
most recent, randomized, controlled phase III trial which compared high-dose 
immunosuppressive therapy and myeloablative HSCT to monthly pulse cyclophosphamide 
treatment [31]. Seventy-five patients suffering from diffuse cutaneous SSc with a high risk of 
lung and/or renal involvement were randomized to AHSCT after myeloablation and 
cyclophosphamide treatment. The 54 months post-treatment event-free survival was 79% in 
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AHSCT group and 50% in control group. The overall survival of AHSCT-treated patients was 
91%, while it was 77% of control patients. Treatment related mortality was 3% in AHSCT 
versus 0% in controls. Based on these results, the SCOT trial reported improved survival and 
supported myeloablative AHSCT as a potential treatment option in diffuse cutaneous SSc. 
Taking all these observations together, AHSCT should be reserved for those diffuse 
cutaneous SSc patients, whose disease is refractory to conventional treatments. Additionally, 
patients with high risk of mortality but without significant irreversible organ damage should 
be also considered [32]. 
 
3.2 Multiple sclerosis 
Multiple sclerosis (MS) is an incurable inflammatory neurological disease, characterized by 
progressive disease course resulting in chronic neurological disability. Regarding the cellular 
background, autoreactive CD4+ T-cells play a crucial role in the development of 
inflammatory plaques, demyelization and consequently contribute to axonal loss [33]. The 
disease course is highly variable between individuals, various form of MS can be 
distinguished based on clinical symptoms, including rapidly evolving severe (RESMS), 
relapsing-remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS) 
forms. In about 85% of cases, the disease starts with relapsing-remitting course, and after 
certain number of relapses the disease enters in secondary progressive phase with 
accumulating disability in 90% of RRMS patients [34]. The current disease-modifying 
treatments include several immune-modulating therapies, such as interferon-beta, glatiramer 
acetate, teriflunomide, fingolimod, natalizumab, and alemtuzumab. These drugs are effective 
in reducing the frequency of relapses in certain subsets of patients; however, they have only 
limited effect on secondary progression leading to increasing degree of disability.  
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After the promising results in experimental models, human phase I/II AHSCT studies began 
in the middle of the 1990s, and so far more than 800 MS patients have received 
transplantation only in Europe. In the last decade, a number of studies reported the 
effectiveness of AHSCT in MS based on the improvements in disease severity measured on a 
10-point ordinal expanded disability status scale (EDSS) and based on magnetic resonance 
imaging (MRI) scans after the therapy. Former MRI studies revealed that inflamed, 
gadolinium-enhancing lesions improve and their gadolinium enhancement abolish in the 
central nervous system after AHSCT [35]. In 2006, a retrospective survey on 178 MS patients 
recruited from the database of EBMT demonstrated a progression free survival of 63% at 42 
months. The overall transplant related mortality was 5.3% [36]. More recently, an Italian 
multi-center study enrolled 74 MS patients in the period from 1996 to 2008 and demonstrated 
a 66% progression-free survival at 5 years after AHSCT, with a 2.7% of TRM [37]. A number 
of studies suggest that AHSCT is most likely to be beneficial in earlier phase of disease 
course [38,39]. Burt et al. reported that the responses in RRMS patients were excellent, 81% 
of them showed improvement in EDSS point after treatment [38]. On the contrary, AHSCT 
was not effective for patients suffering from progressive disease with a more advanced 
disease course and high pre-transplantation disability scores [40]. Recently, Burt et al. 
reported data on 145 MS patients received AHSCT [41]. The authors demonstrated a 
significant improvement in disability in 50% of patients at 2 years with no treatment-related 
mortality. Four-year relapse-free survival was 80% and progression-free survival was 87% at 
4 years. Another novel investigation demonstrated similar results with 78.4% of overall event-
free survival at 3 years with no TRM. The progression-free survival and clinical relapse-free 
survival were 90.9% and 86.3%, respectively, at 3 years [42]. Interestingly, no treatment-
related death was reported in MS following AHSCT in recent studies. This presumably 
reflects a better patient selection and increased experience of transplant centres. 
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Since in the majority of patients, the previously developed neurological damages are often 
irreversible, only limited improvement could be achieved with AHSCT in patients with 
advanced, progressive MS. Nevertheless, transplantation has also been reported to be 
beneficial in RESMS, without effective response to conventional treatments. In numerous 
cases, the disease responds well to AHSCT, its progression stops, often with an unexpected 
recovery from the previous disability [43-45]. 
Moreover, a phase II trial on aggressive form of MS published a few months ago, 
demonstrated that AHSCT can fully halt all detectable CNS inflammatory activity in patients 
with MS for a prolonged period in the absence of any ongoing disease-modifying drugs [46]. 
The joint EBMT-CIBMTR study is the largest and most up-to-date retrospective study 
including 281 MS patients who received AHSCT in 1995-2006 at 25 transplant centres of 13 
countries [47]. Based on the results, five-year probabilities of progression free and overall 
survival were 49% and 93%, respectively. Younger age, relapsing MS and fewer lines of prior 
immune-modifying therapy were associated with better outcomes. Neurological 
improvements during the 12 months following transplant were reported in 52% of relapsing 
patients and in 31% of progressive patients. 
The only available randomized trial in MS is the recently published Autologous Stem cell 
Transplantation International Multiple Sclerosis (ASTIMS) trial [48]. Although patients were 
a mixture of RRMS and SPMS, and only 21 patients were randomized between AHSCT and 
mitoxantrone, a significant reduction was observed in both relapses and new T2 lesions on 
MRI in patients received AHSCT compared to mitoxantrone arm. There is on other ongoing 
international multicentre randomized clinical trial (MIST trial - Stem Cell Therapy for 
Patients With Multiple Sclerosis Failing Alternate Approved Therapy - A Randomized Study) 
comparing AHSCT against FDA approved disease-modifying treatments. This trial is due to 
be completed in 2017 [49]. 
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3.3 Crohn’s disease 
Crohn’s disease (CD) is an autoimmune inflammatory bowel disease affecting all segments of 
the gastrointestinal tract. A combination of immunosuppression and biological therapies is the 
standard therapy, although in severe cases, surgical interventions are also often required [50]. 
Both prospective and case report data are available for AHSCT in CD, demonstrating its 
potential to induce remission of symptoms [51]. A phase I/II study evaluated the safety and 
clinical outcome of AHSCT in 24 patients with severe, refractory CD [52]. Clinical symptoms 
and Crohn’s disease activity index (CDAI) improved before hospital discharge, whereas 
radiographic and colonoscopy findings improved gradually over months to years following 
the transplantation. The percentage of patients in medication-free remission (CDAI<150) 
more than 5 years after transplantation was above 60%. Another small clinical trial with only 
4 patients with refractory CD observed clinical remission in all patients, and in case of three 
patients, both the clinical and endoscopic remissions remained for a longer term despite the 
withdrawal of all medicaments [53]. Based on a subsequent single-arm trial, AHSCT resulted 
in a clinical and endoscopic improvement in five from nine CD patients. However, relapses 
occurred in seven patients during follow-up period, but the disease activity was effectively 
controlled by low-dose corticosteroids and conventional immunosuppressive therapy [54]. In 
the first randomized controlled trial in DC, namely, the Autologous Stem Cell Transplantation 
for Crohn Disease (ASTIC) study, 45 patients with refractory CD were randomized to 
AHSCT (n=23) or standard treatment (n=22) after stem cell mobilization [55]. Only 2 patients 
in AHSCT arm achieved sustained remission, while one in controls. One patient died of 
treatment-related complications, which led to early discontinuation of the trial. Therefore, the 
trial analysis became limited; nevertheless, based on the results, AHSCT improved clinical 
and endoscopic disease activity. 
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3.4 Systemic lupus erythematosus 
Systemic lupus erythematosus, referred to as SLE or lupus, is a clinically heterogeneous, 
chronic systemic autoimmune disease characterized by the presence of autoantibodies 
directed against nuclear antigens and damage of multiple organ systems, including renal, 
cardiovascular, musculoskeletal neural and cutaneous systems. SLE is a relapsing and 
remitting disease, encompassing mild to moderate forms, and also severe, progressive variants 
with a potentially debilitating, even fatal outcome [56].  
Until a few years ago, SLE was one of the most common indications for AHSCT and in the 
last 20 years, more than 110 SLE patients have undergone this treatment in Europe, and more 
than 200 patients worldwide. However, the development of cell-based therapies for SLE has 
undergone a dramatic expansion in this decade [57], and the improving outcomes of 
biological therapies and other standard treatments such as cyclophosphamide or 
mycophenolate mofetil have resulted in decreasing AHSCT in lupus in the last years. Based 
on clinical experience, the rate of disease relapse is high, and the average treatment-related 
mortality rate is about 7-15%, which are still major concerns [23]. In 2006, Burt et al. 
published the largest single-centre report on autologous non-myeloablative HSCT, enrolling 
50 patients with SLE refractory to conventional immune-modulating therapies and either 
organ- or life-threatening visceral involvement [58]. According to their promising results, the 
treatment-related mortality was 4% and with a mean follow-up of 29 months, the overall 5-
year survival was 84%, and probability of disease-free survival at 5 years following HSCT 
was 50%. However, other studies revealed much higher TRM in lupus. A retrospective 
registry survey was carried out by the EBMT/EULAR registry by collecting data from 53 
patients with SLE treated by autologous HSCT in 23 centres [59]. Remission of disease 
activity was achieved by 66% of patients by six months, but 32% of them relapsed during the 
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subsequent six months of follow-up. TRM was 12%, and mortality was associated with a 
longer disease course before AHSCT. Similarly high TRM was reported by Alchi et al., who 
carried out the retrospective survey of 28 SLE patients treated with AHSCT from eight 
centres reported to the EBMT [60]. The five-year overall survival was 81%, but disease-free 
survival was only 29% with a high relapse incidence (56%) and TRM (15%). Regarding the 
combination of AHSCT with other immunemodulatory treatments, a previous study showed 
that administration of fludarabine and anti-CD20/B-cell specific biologics with AHSCT 
turned out to be advantageous in lupus [61]. These studies revealed the relatively high 
procedural risks and mortality, and despite the initial interest, clinicians and researchers 
looked towards other effective and promising treatments [62] and the number of AHSCT 
declined in lupus. Nevertheless, AHSCT is still one of the accepted therapies and may be 
considered in severe refractory SLE as a salvage strategy [63]. 
 
3.5 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is characterized by the inflammation of the synovial tissue and 
progressive joint destruction. Although RA usually does not lead to life-threatening 
complications, it often results in significant deterioration in the quality of life. Biologics and 
early aggressive disease-modifying antirheumatic drugs (DMARDs) are very effective in RA, 
especially in early phase of disease. Although numerous new pharmacological therapies 
emerged for RA in the last decade, there are still about 15% of patients who do not response 
to any modern DMARDs, or biologics. AHSCT seems to be a possible treatment option when 
the disease is refractory to other treatments and the patient’s clinical condition is good enough 
for the procedure [64]. Until now, more than 80 RA patients received AHSCT in Europe. 
Based on a former study on 14 patients with active, destructive, refractory RA, AHSCT 
treatment led to significant clinical amelioration, and 67% of patients reached ACR50. Clear 
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improvement was observed in the activity index and in joint function, moreover the 
radiological analysis found reduction in the cartilage destruction [65]. Nevertheless, the 
ability of AHSCT to maintain a sustained ACR 70 response was low with only 28% achieving 
a progression free survival at the end of three-year follow-up [66]. An EBMT/ABMTR 
database study on 73 patients reported that the transplantation was generally well tolerated 
without TRM. On the other hand, the initial good responses were frequently followed by early 
relapses, although, the disease activity did not reach the pre-treatment level, and the patient 
becomes responsive to conventional treatment modalities including DMARDs and biologics 
again [67]. The early relapses in RA after AHSCT might be due to the surviving autoreactive 
T-cells in inflamed synovia and pannus, where the lymphoablative treatment do not have 
sufficient effects; which raises the possibility that eradication of these intraarticular T-cell 
clones with special myeloablative conditioning treatment might prolong the remission and 
symptom-free period in RA after transplantation [68]. Of note, a multicenter randomized 
controlled trial in RA was established (Autologous Stem cell Transplantation In Rheumatoid 
Arthritis - ASTIRA); however, it was closed due to the failure to recruit sufficient patients. In 
conclusion, with the advent of rituximab and other biologics, the number of AHSCT 
performed for RA patients decreased worldwide and RA remained no longer an indication for 
AHSCT. 
 
3.6 Juvenile idiopathic arthritis 
Based on the last Annual Report of EBMT, until now 89 children with juvenile idiopathic 
arthritis (JIA), mostly the systemic form, have been treated with AHSCT in Europe. The high 
transplant-related mortality (9-11%) is still a major concern [23]. After a median follow-up of 
3 years, 53% of the patients were still in complete drug-free remission, while 18% showed 
only partial response, and in 21% of patients there was no improvement [69,70]. In a long-
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term follow-up study, the prolonged drug-free remissions were confirmed, although the 
transplant-related mortality was still high [71]. Similar to RA, the treatment of JIA has also 
changed with the emerge of biological agents, nevertheless, a few sporadic RA and JIA 
patients are still reported to EBMT database. 
 
3.7 Systemic vasculitides 
Systemic vasculitides are a complex group of disorders characterized by the inflammation of 
blood vessels leading to tissue and organ injury. So far, less than 50 patients were treated with 
AHSCT in Europe. A recent retrospective registry-based analysis summarized 15 patients 
with various forms of vasculitis [72]. Fourteen patients received AHSCT, while one patient 
underwent allogeneic stem cell transplantation. In three patients, further transplantation was 
necessary due to relapse. The overall response to treatment was 93%, with 46% complete 
response and 46% partial response rates. Three patients died during the follow-up, due to 
different reasons (advanced disease course, cancer and graft-versus-host disease). Similar 
results were observed in other studies investigating only four and two AHSCT-treated patients 
[73,74]. 
 
3.8 Chronic inflammatory demyelinating polyneuropathy 
Chronic inflammatory demyelinating polyneuropathy (CIDP), which is an acquired immune-
mediated disorder, is the most common chronic autoimmune sensorimotor neuropathy. 
Around 70-80% of CIDP patients respond to moderate doses of immunomodulating therapy 
including corticosteroids, intravenous immunoglobulin and plasma exchange. However, some 
patients need high doses of immunosuppression continuously. If these increased doses are 
poorly tolerated, AHSCT may be considered. Until now, more than 30 CIDP patients received 
AHSCT in Europe. Although, only a limited number of studies were conducted on the effect 
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of AHSCT on CIDP, the results are promising. In a case report, the neurological status of a 
CIDP patient improved after AHSCT [75]. Additionally, in the last years, other clinical 
studies also reported a relatively small number of CIDP patients, who showed clinical 
improvement after AHSCT [76,77]. Moreover, a phase II trial Hematopoietic Stem Cell 
Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy is currently ongoing 
[78]. 
 
3.9 Autoimmune cytopenia 
Autoimmune cytopenias are characterized by the production of antibodies against blood cells 
and include immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia 
(AIHA), autoimmune neutropenia (AIN), and various combinations of these conditions. 
These disorders may develop idiopathically, or can be associated with other malignant or non-
malignant diseases, such as lymphoid malignancies, autoimmune disorders or infections. The 
treatment of the malignant, autoimmune or infectious diseases may induce the remission of 
secondary autoimmune cytopenia, as well. In primary cytopenia, specific immunosuppressive 
therapy is needed; however, resistance to immunomodulating agents or relapse after therapy 
is not rare. For steroid-refractory patients with ITP and AIHA, splenectomy is usually 
recommended, while in AIN, granulocyte colony-stimulating factor (G-CSF) could be 
administered. In the last decade, biologics became a promising treatment modality in 
autoimmune cytopenias, as well [79]. However, severe, refractory autoimmune cytopenia is 
still a challenge. According to a study on AHSCT in the treatment of severe refractory 
autoimmune cytopenia, the transplantation may induce a prolonged good clinical response, 
albeit transplant-related mortality is remarkably high, circa 8% [23]. Based on the EBMT 
registry, more than 75 patients were treated with AHSCT so far. 
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3.10 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM) is a common organ-specific autoimmune disease 
characterized by the destruction of insulin-producing β-cells in islets of Langerhans within the 
pancreas [80]. For the appropriate administration, immune-suppression required to be 
launched within the first 12 weeks of the disease onset. Albeit glucocorticosteroids have 
strong immune-suppressive properties, in T1DM they can induce islet-cell apoptosis and 
further deterioration of the disease [81].  
In a clinical study, AHSCT was carried out on patients with newly onset T1DM. From the 15 
patients received AHSCT, 14 patients became insulin-free and only one resumed insulin use 1 
year after AHST. Serum levels of hemoglobinA1c were maintained at less than 7% in 13 of 
14 patients, and there was no mortality [82]. For the first time, this study indicated that 
patients with T1DM can become insulin free with normal HgbA1c for extended periods of 
time. Two years later, Couri at al. reported on 23 patients with T1DM undergoing AHSCT 
and showed that C-peptide levels increased after the procedure [83]. The level of C-peptide 
refers to the islet cell mass and its increase after transplantation clearly indicates the 
restoration of islet cells. Twenty from 23 patients became insulin-free, and the mortality was 
zero. A multicenter study on 65 patients reported that 59% of patients achieved remission at 6 
months after AHSCT and 32% remained insulin-free even after 48 months [84]. A recent 
meta-analysis demonstrated that 58,9% of 149 T1DM patients became insulin independent 
after AHSCT during a mean follow-up period of 16 months [85]. Nevertheless, the question is 
still open whether a three year disease-free survival expectation is worth confronting with 
transplant-related complications and an AHSCT related reduction in the bone marrow 
functional reserve. 
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4. Discussion  
 
Over the last two decades, there has been an extensive development of AHSCT for 
autoimmune diseases and the procedure has gradually translated into clinical practice. 
Although the transplant-related complications and mortality are still a major issue, the 
increasing knowledge on AHSCT resulted in a significant improvement in both the efficacy 
and safety of its administration in various autoimmune diseases. In the beginning, the rate of 
treatment-related mortality was over 10%; however, this high rate has decreased with an 
improved patient selection and increased experience of transplant centres. Previously, based 
on the safety and toxicity considerations, AHSCT was reserved for unique, and often end-
stage cases of severe autoimmune diseases not responding to a wide range of 
immunosuppressive treatments. Consequently, the procedure further debilitated the patients’ 
poor general health status and frequently led to serious treatment-related complications, even 
death. However, subsequent studies demonstrated that AHSCT is hardly beneficial in end-
stage patients with irreversible organ damage, and getting AHSCT in a very early stage of 
autoimmune diseases, before any permanent organ damage or disability occur, results in less 
complications and better clinical outcome. 
In addition to the type and stage of autoimmune disease, the conditioning regimen also 
determines the sustained clinical remissions or even cure. In the beginning, myeloablative 
protocols were administered mostly, however this aggressive conditioning protocol 
accompanied with a significantly high rate of mortality. On the contrary, non-myeloablative 
conditioning modality was better tolerated and accompanied with lower risk of treatment-
related mortality. Today, the aim of conditioning regimen is lymphoablation only, and 
myeloablation has become an unwanted side effect. 
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Even though over 100 studies on AHSCT in autoimmunity have been published, there are still 
a number of unanswered questions regarding the cellular background of the immune-
modulating effect during treatment. The restoration of regulatory immune mechanisms may 
play a role in the clinical amelioration; however, further functional assessments of the 
repopulated immune system from stem cells have to be carried out to understand mechanisms 
behind inhibition of autoreactivity. 
It is also important to underline the relative high chance of disease relapse after AHSCT. 
Unlike autologous HSCT, allogeneic HSCT seems to offer a more curative potential since the 
auto-reactive immune system is replaced by a new one. Although autologous HSCT can 
restore the self-tolerance, cannot eliminate genetic risk factors for the development of 
autoimmune diseases and therefore relapses are not unexpected in the treated patients. On the 
contrary, allogeneic HSCT offers a completely new immune system for the recipient with a 
higher chance for a definitive cure. Nevertheless, the high risk of graft-versus-host disease 
limits its wide clinical use, and the complications of its ablative treatment are also associated 
with significant treatment related mortality [86]. 
For the appropriate evaluation of the risks of AHSCT, it is important to consider the most 
common complications of ablative therapy, including infections with aplasia, bleeding, and 
organ failures (such as cardio-respiratory system). The period of pancytopenia is 
unfortunately long and patients are exposed to high risk of infection and haemorrhage until 
the re-infused autologous stem cells repopulate the peripheral blood with mature progeny 
[15]. In order to shed light on the real efficacy and the suitable therapeutic role of AHSCT in 
autoimmune diseases, successful completion of further large scale trials, including 
randomized controlled studies is mandatory, which are actually available for a few 
autoimmune diseases in a limited number only (Table 2). 
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5. Conclusions and future perspectives 
 
The development of autoimmune diseases is driven by an intricate interplay between genetic 
and environmental factors. However, AHSCT in the therapeutic arsenal can only target just 
one element of the pathogenesis; consequently, the final healing or long-lasting cure cannot 
always be achieved and the good initial responses are commonly followed by early relapses. 
Nevertheless, the intensity of disease activity does not reach the pre-treatment level, and the 
patients often become responsive to conventional treatment options, such as DMARDs, or 
biologics again. Currently, it is not clear if the immune resetting after AHSCT is temporary, 
neither which mechanisms are responsible for the clinical remission. However, the 
considerable rate of post-transplantation relapse suggests that further immunological 
interventions are still required after AHSCT. Understanding the mechanisms of disease 
remission and relapse are essential for personalizing AHSCT regimen and post-
transplantation treatment. 
In the last five years, the best results with AHSCT have been reported for patients with 
multiple sclerosis and systemic sclerosis. In Crohn’s disease and type 1 diabetes mellitus, a 
few promising reports were also published. In contrast, high procedural risks and mortality 
were revealed in other conditions such as SLE, RA and JIA; and due to the development of 
novel, effective and low-risk biological agents, the number of AHSCT has declined strongly 
in these diseases.  
It is important to underline, that besides its beneficial effects in some selected diseases, 
AHSCT remained still a controversial procedure. After the treatment, besides the possibility 
of treatment-related complications and relapse of the original autoimmune disorder, various 
other autoimmune diseases can also develop both organ specific and systemic ones [87]. 
 23 
Development of autoimmune thrombocytopenia, acquired hemophilia, autoimmune hemolytic 
anemia, Evans’ syndrome, autoimmune thyroiditis and ulcerative colitis have been reported 
following AHSCT. Rheumatoid arthritis and spondylarthropathy can also develop, 
additionally, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could be 
a major complication, as well. The previous chemotherapy and irradiation during conditioning 
play presumably an important role in the development of these complications. 
The effects of AHSCT on fertility are another important issue. Since there is a high 
prevalence of young females suffering from autoimmune disease, fertility preservation is one 
of the major factor in quality of life. Although there are only a limited data available on 
fertility after AHSCT in autoimmune diseases, recently, a retrospective EBMT study 
demonstrated a relative promising fertility finding with 22 pregnancies from 324 adult female, 
and 68% of them achieved a healthy live birth [88]. 
In summary, based on the lessons we learned in SLE and RA, it should be conceded that the 
current efficacy of AHSCT in MS and SSc are fundamentally based on the lack of effective, 
disease-specific treatment options in these diseases. However, in the near future, the 
accelerated technological improvement will hopefully lead to the better understanding of 
disease pathogenesis, which will results in further development of target specific therapeutic 
modalities even in MS and SSc, as well. Therefore, the range of indications for AHSCT in 
autoimmune diseases will presumably become substantially narrower in the next decade. 
Alternatively AHSCT combined with individually-tailored biologics may give better results. 
The other possibility is that in the future allogeneic stem cell transplantation may have a more 
substantial role in the therapeutic arsenal of the management of autoimmune disease however 
conditioning-related mortality needs to be reduced. Better conditioning regimens, which are 
better tolerable, need to be implemented for this alternative. 
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On the other hand, patients who have undergone stem cell therapy and relapse afterwards may 
show better response to conventional therapy/biological therapy compared to responses before 
ASCT. We assume that the combination therapy of AHSCT and modern targeted biologics 
can open novel avenues in the better managements of patients with systemic autoimmune 
diseases giving better perspectives to these patients. 
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Article highlights 
 
 Intricate interplay of various immune cells contributes to the development of tolerance 
after AHSCT 
 AHSCT carried out before any irreversible organ damage leads to the best clinical 
outcome 
 Less treatment-related complications would make the application of AHSCT more 
widespread 
 Impact of AHSCT decreased in some diseases due to the development of other novel 
treatments 
 In certain autoimmune diseases AHSCT can be good choice when conventional 
therapy failed 
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Tables 
 
Autoimmune disease 
Number of  
treated patients 
Multiple sclerosis 801 
Systemic sclerosis 433 
Crohn's disease 155 
Systemic lupus erythematosus 113 
Juvenile chronic arthritis 89 
Rheumatoid arthritis 85 
Vasculitides 49 
Immune thrombocytopenic purpura 31 
Chr. inflamm. demyelinating polyneuropathy 31 
Autoimmune hemolytic anemia 25 
 
Table 1. The list of the top 10 autoimmune diseases treated with AHSCT in Europe 
between 1995 and 2015, according to the latest annual report on EBMT database [19]. 
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Trial Disease Status Treatment Trial number Reference 
ASSIST (Autologous Stem Cell 
Transplantation for Refractory 
Systemic Lupus Erythematosus) 
Systemic sclerosis Completed 
ASCT vs. 
Cyclophosphamide 
NCT00750971 [29] 
ASTIC (Autologous Stem Cell 
Transplantation for Crohn's 
Disease) 
Crohn's disease Terminated Early vs. Late ASCT NCT00297193 [55] 
ASTIMS (Autologous Stem cell 
Transplantation International 
Multiple Sclerosis) 
Multiple sclerosis Completed 
ASCT vs. 
Mitoxantrone 
Eudract 2007 - 000064-24 [48] 
ASTIS (Autologous Stem cell 
Transplantation International 
Scleroderma trial) 
Systemic sclerosis Completed 
ASCT vs. 
Cyclophosphamide 
NTR338 [30] 
MIST (Stem Cell Therapy for 
Patients With Multiple Sclerosis 
Failing Alternate Approved 
Therapy- A Randomized Study) 
Multiple sclerosis Ongoing 
ASCT vs. Standard 
therapy 
NCT00273364 [49] 
SCOT (Scleroderma: 
Cyclophosphamide or 
Transplantation) 
Systemic sclerosis Completed 
ASCT vs. 
Cyclophosphamide 
NCT00114530 [31] 
 
Table 2. Prospective randomized controlled studies on AHSCT in autoimmune diseases. 
 
 
 
 
 
